Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
“The medicine comes for free, just pay us for the inhaler” should be the marketing slogan for this group of therapeutics. Nebulizers are good business: hard to copy as a delivery system, they are a great opportunity to ‘evergreen’ off-patent antibiotics. The inhalational route to administer antibiotics is clearly attractive. Continue reading Aerosolized Antibiotics & Selling Nebulizers
The economics of developing antibacterials is a frustrating topic to address. There are unique aspects to the antibiotic market which sets it apart from other medicines, esp. the unique societal aspects of antibiotic use which go beyond the benefit to the individual. IDSA has spoken out in various publications (“Bad Continue reading It’s Not a Free-Enterprise Market, Stupid!
In a publication from 2007, investigators from Arrow Pharmaceuticals told us that A-60444 (later renamed to RSV-604) was already in Phase 2. Since then, it has been very quiet about this compound. Some have suggested that Novartis has stopped development [1], an impression supported by the fact that the drug is Continue reading Following The Publication Trail of Two RSV Drugs